ライフサイエンスコーパス: phototherapy

1 nonsystemic treatment (topical therapies or phototherapy).

2 n combination with narrowband UV-B (NB-UV-B) phototherapy.

3 mization of laser parameters for nondamaging phototherapy.

4 find broad applications in biotechnology and phototherapy.

5 ne was significantly reduced with aggressive phototherapy.

6 to treat plaque psoriasis is narrowband UV-B phototherapy.

7 to undergo either aggressive or conservative phototherapy.

8 hotoadaptation for the dosimetry of UV-based phototherapy.

9 s, infliximab, methotrexate, apremilast, and phototherapy.

10 ne growth retardation who did not respond to phototherapy.

11 It may be prescribed in conjunction with phototherapy.

12 rse angiographic outcomes were attributed to phototherapy.

13 duction may eventually decrease the need for phototherapy.

14 unomodulant/immunosuppressive medications or phototherapy.

15 e severe jaundice and require treatment with phototherapy.

16 ar with the other psoriasis therapies except phototherapy.

17 al period, are treated with blue-green light phototherapy.

18 on human dermal fibroblasts treated with RL phototherapy.

19 y offers a new approach for efficient cancer phototherapy.

20 istance frequently occurring in conventional phototherapy.

21 of individual patient outcome at the end of phototherapy.

22 radiotherapy, immunotherapy, photodynamic or phototherapy.

23 iplet-triplet annihilation upconversion, and phototherapy.

24 icals or heat, allowing for effective cancer phototherapy.

25 o were candidates for home- and office-based phototherapy.

26 to oxygen-containing compounds following RL phototherapy.

27 suppressive TIME when working together with phototherapy.

28 iciency of large-scale reactions and in vivo phototherapy.

29 utic agents are also observed in combination phototherapy.

30 diate/complex repair, flap, graft, and laser/phototherapy.

31 at 17 weeks, 1 week after discontinuation of phototherapy.

32 tional age, and hyperbilirubinemia requiring phototherapy.

33 no association were among patients receiving phototherapy.

34 chemical upconversion, light-harvesting, and phototherapy.

35 ations in photocatalysis, photovoltaics, and phototherapy.

36 vanced materials for organic electronics and phototherapy.

37 the complex oxidation mechanism of BR during phototherapy.

38 ications of photostimulation, photometry and phototherapy.

39 -Najjar syndrome that was being treated with phototherapy.

40 /DVDMS nanotheranostics (nanoDVD) for cancer phototherapy.

41 tions in photocatalysis, nanoelectronics and phototherapy.

42 thermore, these mice did not benefit from UV phototherapy.

43 at risk for kernicterus and require lifelong phototherapy.

44 lization; and (4) at least 1 readmission for phototherapy.

45 processes and image-guided precise conformal phototherapy.

46 ctivity and cure of seasonal depression with phototherapy.

47 utaneous GVHD with narrowband UV-B (NB UV-B) phototherapy.

48 ppressants, extracorporeal photopheresis, or phototherapy.

49 age Ib) disease and began ultraviolet (UV) B phototherapy.

50 to filtered sunlight and 223 to conventional phototherapy.

51 ter clobetasol treatment but not after UV-A1 phototherapy.

52 ces with gender, apneic spells, jaundice, or phototherapy.

53 emitting MS were treated with narrowband UVB phototherapy.

54 ate compared with treatment with oral agents/phototherapy.

55 (66%, mostly anti-tumor necrosis factor) and phototherapy (15%) (P < .001).

56 After 1 month of NB-UV-B phototherapy, 16 mg of afamelanotide was administered su

57 The patient was initiated on NB UV-B phototherapy 3 times per week, resulting in clinically s

58 P = .02) and at increased risk of requiring phototherapy (3 of 10 [30.0%] vs 6 of 91 [7.0%]; P = .04

59 r (-14.1%), graft repair (-12.0%), and laser/phototherapy (-6.6%; P < .001).

60 100 patients (25.6%) receiving office-based phototherapy achieved clear/almost clear skin, and 206 (

61 This improved phototherapy achieves a complete cure of oral cancer xen

62 The effect of lung phototherapy administered during CO poisoning was also s

63 Phototherapy administered during severe CO poisoning lim

64 Only 7% of phototherapy-affected MVPs (150 out of 2,108) correlate

65 sitive predictive value 88.0%), and starting phototherapy after age 13 days increased this risk 3.5-f

66 In addition, the therapeutic efficacy of phototherapy against MC903-driven AD could be increased

67 rained by the lack of appropriate multimodal phototherapy agents exhibiting an ideal tissue penetrati

68 0 times over single treatment with SN-38 and phototherapy alone, respectively.

69 2, 129 patients (32.8%) receiving home-based phototherapy and 100 patients (25.6%) receiving office-b

70 from 12 patients undergoing narrow-band UVB phototherapy and 12 corresponding healthy controls revea

71 the rates of death were 13% with aggressive phototherapy and 14% with conservative phototherapy for

72 376 [48.0%] female), 393 received home-based phototherapy and 390 received office-based phototherapy,

73 rowband UV-B monotherapy vs combined NB-UV-B phototherapy and afamelanotide.

74 physical properties well-suited for clinical phototherapy and cancer imaging.

75 Rates of death in the aggressive-phototherapy and conservative-phototherapy groups were 2

76 months) who were candidates for systemic or phototherapy and had a Psoriasis Area and Severity Index

77 The application of CNPs for drug delivery, phototherapy and immunotherapy will be described in deta

78 ation; ii) and the antitumor effects between phototherapy and immunotherapy.

79 superseded by various forms of radiotherapy, phototherapy and local tumour resection, often administe

80 go treatments with systemic effects (such as phototherapy and oral steroids) or a new mental health d

81 Although phototherapy and T cell suppression therapy have been wi

82 Studies have found that phototherapy and/or neonatal jaundice may be associated

83 Beyond their use in drug/gene delivery, phototherapy, and bioimaging, recent studies have reveal

84 uated, as compared with 90% for conventional phototherapy, and had a higher mean level of irradiance

85 d UV index, irradiance, latitude, history of phototherapy, and history of sunburn.

86 , cyclosporine, methotrexate, mycophenolate, phototherapy, and many novel agents are less certain.

87 lophosphamide, long-wavelength ultraviolet A phototherapy, and monoclonal antibodies such as denileuk

88 and include biological and cytotoxic drugs, phototherapy, and monoclonal antibodies that are directe

89 osuppressive/chemotherapeutic interventions, phototherapy, and other means.

90 ected therapies, such as topical steroids or phototherapy, and systemic therapies, such as monoclonal

91 scue therapy use, including topical therapy, phototherapy, and systemic therapy, was permitted from d

92 e incidence of MI in the TNF inhibitor, oral/phototherapy, and topical cohorts were 3.05, 3.85, and 6

93 y and efficacy as compared with conventional phototherapy are unknown.

94 pare narrow-band UVB, UVA, and visible light phototherapy as second-line, adjunctive treatments in ad

95 Aggressive phototherapy, as compared with conservative phototherapy

96 e in bilirubin levels and were not receiving phototherapy at least 78 weeks after vector administrati

97 below 300 mumol per liter in the absence of phototherapy at the end of follow-up (mean [+/-SD] basel

98 .5%; 95% CI, 4.7%-6.1%) and readmissions for phototherapy by 53% (absolute risk reduction, 1.8%; 95%

99 When used in conjunction with phototherapy, calcitriol ointment should be applied afte

100 Phototherapy can offer a safe and non-invasive solution

101 other systemic agents or phototherapy (oral/phototherapy cohort), and 5075 were not treated with TNF

102 acitretin combination, and then biologic and phototherapy combination.

103 Home-based phototherapy, compared to office-based phototherapy, was

104 apy group monthly for 4 months while NB-UV-B phototherapy continued; the other group continued to rec

105 adalimumab (CRP, TNF-a, IL-6, and GlycA) and phototherapy (CRP and IL-6) compared with that observed

106 trate that the combination of gene, drug and phototherapy delivered through a prophylactic hydrogel p

107 Noninvasive transesophageal phototherapy delivered to murine lungs via an optical fi

108 thoracotomy, we assessed the effect of lung phototherapy delivered to murine lungs via an optical fi

109 Subthreshold retinal phototherapy demonstrated clinical efficacy for the trea

110 Furthermore, fluorescence-imaging-guided phototherapy demonstrates that this phototheranostic cou

111 tion (n = 17) normalized B(T) and eliminated phototherapy dependence.

112 Aggressive phototherapy did not significantly reduce the rate of de

113 Aggressive phototherapy did reduce rates of neurodevelopmental impa

114 Conventional phototherapy does not prevent hyperbilirubinemia or elim

115 Phototherapy during birth hospitalizations was reduced b

116 my of Pediatrics phototherapy threshold; (3) phototherapy during the birth hospitalization; and (4) a

117 sue penetration capacity of molecular light, phototherapy employing the synergistic effect of a photo

118 al treatment who were treated with intensive phototherapy, exchange transfusion, or red blood cell tr

119 overview of the current clinical progress of phototherapies for cancer and discuss the emerging precl

120 ed trials addressing systemic treatments and phototherapy for AD.

121 e psoriasis who used systemic medications or phototherapy for at least 3 months from December 1, 1990

122 iasis in children, narrow band ultraviolet B phototherapy for atopic dermatitis and psoriasis, use of

123 ds great promise for revolutionizing at-home phototherapy for chronic infected wounds.

124 ssive phototherapy and 14% with conservative phototherapy for infants with a birth weight of 751 to 1

125 in the delayed cord clamping groups required phototherapy for jaundice.

126 recalcitrant lesions in more severe disease; phototherapy for moderate disease; and systemic agents i

127 Future development and scaling up of lung phototherapy for patients with CO exposure may provide a

128 phototherapy was noninferior to office-based phototherapy for PGA and DLQI in the overall population

129 hototherapy was as effective as office-based phototherapy for plaque or guttate psoriasis in everyday

130 b, etanercept, infliximab, or ustekinumab or phototherapy for psoriasis.

131 ered sunlight was compared with conventional phototherapy for the treatment of hyperbilirubinemia in

132 ates on living systems, and lead to clinical phototherapy for the treatment of infections.

133 red sunlight was noninferior to conventional phototherapy for the treatment of neonatal hyperbilirubi

134 port describes the successful use of NB UV-B phototherapy for the treatment of sclerotic chronic cuta

135 practice of phototesting prior to commencing phototherapy, for therapeutic failure in sites such as t

136 the aggressive-phototherapy and conservative-phototherapy groups were 24% and 23%, respectively (rela

137 Enhancements in topical therapy and phototherapy have also increased the armamentarium of tr

138 e UV index, irradiance, latitude, history of phototherapy, history of sunburn, or occupational exposu

139 ) or more in 10 newborns; treatment involved phototherapy in 136 cases and exchange transfusion in 5.

140 ious infection compared with retinoid and/or phototherapy in adults.

141 mmunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during c

142 th, underscoring the synergistic benefits of phototherapy in combination with antibiotic treatment.

143 The course of phototherapy in newborn rats provides fast recovery afte

144 thylation pattern was reversed at the end of phototherapy in patients showing excellent clinical impr

145 significant obstacle to developing efficient phototherapy in vivo.

146 ising their use in photoacoustic imaging and phototherapy, in addition to their promise for neutron c

147 Phototherapy (including photothermal therapy, PTT; and p

148 Specifically, RL phototherapy increased the expression of MMP1, which cod

149 Phototherapy induced a vitD and type I IFN signature tha

150 ilirubin levels and childhood asthma without phototherapy intervention in the Collaborative Perinatal

151 use of filtered sunlight for the purpose of phototherapy is a safe and efficacious method for reduci

152 Phototherapy is a standard treatment for severe neonatal

153 Phototherapy is an effective treatment, but a drug thera

154 Office-based phototherapy is cost-effective for psoriasis but difficu

155 The efficacy of photosensitizers in cancer phototherapy is often limited by photobleaching, low tum

156 Home-based phototherapy is patient preferred but has limited clinic

157 The major mechanism of BR elimination during phototherapy is photoisomerization, while a minor, less

158 However, the clinical application of tumor phototherapy is severely restrained by the lack of appro

159 burden in areas where effective conventional phototherapy is unavailable.

160 The long-term safety of narrowband UVB phototherapy is uncertain.

161 Narrowband UV-B (NB-UV-B) phototherapy is used extensively to treat vitiligo.

162 Late Impact of Getting Hyperbilirubinemia or Phototherapy (LIGHT) birth cohort.

163 gics, such as etanercept or adalimumab, with phototherapy likely results in greater reduction in dise

164 several cellular mechanisms underpinning RL phototherapy, little is known about the transcriptional

165 ring respiratory support, jaundice requiring phototherapy, major congenital anomalies, neonatal hypog

166 UV-A1 phototherapy may be a promising alternative treatment op

167 UV-A1 phototherapy may be considered a potential second-line t

168 Given concerns that some treatments, such as phototherapy, may increase skin cancer risk, this findin

169 h MN-assisted PDT and PTT are light-mediated phototherapy methods and have unique advantages, includi

170 soriasis, and open studies suggest that this phototherapy might improve atopic eczema.

171 The most frequently used phototherapy modality is UV-B, whereas methotrexate is t

172 Ruxolitinib cream and narrow-band UVB phototherapy (NB-UVB) independently promote repigmentati

173 sible light limits clinical applicability of phototherapy, necessitating use of deep tissue penetrati

174 ced arthritis rat model, FA-PEG-NTK-mediated phototherapy notably alleviated synovial hyperplasia and

175 ial tags to SERS imaging-guided and targeted phototherapy of cancer cells by controlling the laser po

176 The utility of these molecules for phototherapy of cancer is confirmed by the drastic incre

177 In CO-poisoned mice, phototherapy of exposed lungs at 532, 570, 592, and 628

178 results uncover the clinical significance of phototherapy of intraventricular hemorrhage in 4-day old

179 ese findings shed light on the mechanisms of phototherapy of intraventricular hemorrhage that can be

180 al application or endogenous generation, via phototherapy, of inhibitory MR1 ligands.

181 which may underlie the beneficial effect of phototherapy on psoriasis.

182 ory approach, the effect of ultraviolet (UV)-phototherapy on the transcriptome of immune cells of MS

183 ess the effects of direct lung illumination (phototherapy) on the CO elimination rate.

184 When treated with phototherapy or exchange transfusion, total serum biliru

185 portion of patients developed erythema after phototherapy or had a flare in their eczema sufficient t

186 c applications, alone or in combination with phototherapy or radiotherapy, have also been pondered.

187 aque-type psoriasis, and were candidates for phototherapy or systemic therapy.

188 vere plaque psoriasis who are candidates for phototherapy or systemic therapy.

189 screening and baseline; were candidates for phototherapy or systemic therapy; or had psoriasis that

190 ry treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments.

191 (PDT), also known as photoradiation therapy, phototherapy, or photochemotherapy, involves the use of

192 naive and received other systemic agents or phototherapy (oral/phototherapy cohort), and 5075 were n

193 evaluated therapies combining biologics with phototherapy, oral medications, or other biologic agents

194 ments used for moderate-to-severe psoriasis (phototherapy, oral systemic, or biologic therapies) were

195 ht and in 1% of those receiving conventional phototherapy (P<0.001), but no infant met the criteria f

196 and 35.6% [95% CI, 18.2% to 53.1%] for UV-A1 phototherapy [P = .006]).

197 Prolonged, daily phototherapy partially controls the jaundice, but the on

198 or medium-dose UV-A1 (50 J/cm(2)) home-based phototherapy, performed 4 times weekly for 3 months.

199 clonal antibody (mAb)-based, highly specific phototherapy (photoimmunotherapy; PIT) that uses a near

200 avenues to enhance the beneficial effects of phototherapy protocols and sun protection.

201 apies which include topical corticosteroids, phototherapy (psoralen with UVA or UVB), topical chemoth

202 We assessed the safety and tolerability of phototherapy (PT) with MLu in patients undergoing percut

203 Phototherapy (PT), a light activated treatment modality,

204 nalysis, it was observed that treatment with phototherapy (rate ratio [RR], 1.09 [95% CI, 0.62-1.93];

205 r inflammation and that TNF-a inhibitors and phototherapy reduce CRP and IL-6.

206 nlight exposure and when determining optimal phototherapy regimens.

207 rapy, and for individualised optimisation of phototherapy regimes to improve clinical outcome.

208 al impairment (26%, vs. 30% for conservative phototherapy; relative risk, 0.86; 95% CI, 0.74 to 0.99)

209 tosynthetic nanothylakoid (FA-PEG-NTK)-based phototherapy reprogrammes macrophages from M1 to anti-in

210 ination of afamelanotide implant and NB-UV-B phototherapy resulted in clinically apparent, statistica

211 of immune and epidermal cells induced by UVB phototherapy returned the epidermis back to the healthy

212 MS patients treated with UVB phototherapy showed an increase in induced Tregs and tol

213 phototherapy, as compared with conservative phototherapy, significantly reduced the mean peak serum

214 th weight of >=4500 g, respiratory distress, phototherapy, stillbirth or neonatal death, or shoulder

215 Three trials on systemic therapy/phototherapy suggested that induction of remission resul

216 ily treated with exposure to blue light, and phototherapy systems have been developed for low-resourc

217 Two custom phototherapy systems were constructed from affordable ma

218 d here utilizes the 48-year-old mechanism of phototherapy that is commonly implemented in the treatme

219 After UV-A1 phototherapy, the VAS score for burning and/or pain (MD,

220 ond highlighting an alternative strategy for phototherapy, this proof-of-concept study affords a faci

221 or above the American Academy of Pediatrics phototherapy threshold.

222 exceeding the American Academy of Pediatrics phototherapy threshold; (3) phototherapy during the birt

223 of nanoDVD are shown to be synergistic with phototherapy to improve antitumor efficacy in vitro and

224 The resulting jaundice may be managed with phototherapy to isomerize the biosynthetic 4Z,15Z-biliru

225 Current therapy relies on phototherapy to prevent kernicterus, but liver transplan

226 It is unclear whether aggressive phototherapy to prevent neurotoxic effects of bilirubin

227 therapy (e.g., chemotherapy, immunotherapy, phototherapy) to eliminate residual lesions.

228 PIT), a next-generation cancer cell-targeted phototherapy, to establish CAF-targeted NIR-PIT.

229 TNF inhibitors, other systemic therapies, or phototherapy (topical cohort).

230 Descriptive study comparing TSB levels and phototherapy use before and after recalibration at Kaise

231 lamp types appear to be of similar efficacy, phototherapy using a selective broadband source may be a

232 This study explores platinum(II) phototherapy using cycloplatinated compounds with bident

233 stoperative encounters, cosmetic procedures, phototherapy visits, and Mohs surgery encounters.

234 Phototherapy was administered twice a week for 12 weeks.

235 n this randomized clinical trial, home-based phototherapy was as effective as office-based photothera

236 in a significant clinical improvement, UV-A1 phototherapy was inferior to the current gold standard t

237 Home-based phototherapy was noninferior to office-based phototherap

238 cohort study of infants born at a time when phototherapy was unavailable, neonatal hyperbilirubinemi

239 based phototherapy, compared to office-based phototherapy, was associated with better treatment adher

240 ours of age who received at least 5 hours of phototherapy; we prespecified a noninferiority margin of

241 including the development of erythema during phototherapy, were similar for the two lamp types.

242 is contribution targets a general problem in phototherapy, which is how to interrogate the light-trig

243 Phototherapy-which includes photothermal therapy (PTT) a

244 get tissues and demonstrate that it supports phototherapies with different photosensitizers.

245 Consistent phototherapy with 33-103 uW/cm(2) *nm for 9.2 +/- 1.1 ho

246 Phototherapy with blue-green light can be applied to red

247 Noninvasive phototherapy with functional preservation is considered

248 and minoxidil showed some benefit in AA, and phototherapy with narrowband UVB was shown to be effecti

249 Phototherapy with UV light is a standard treatment for p

250 d phototherapy and 390 received office-based phototherapy, with 350 (44.7%) having skin phototype (SP